About

Breaking News

Guselkumab Demonstrates Superiority Versus Placebo and Ustekinumab in Phase 3 Crohn’s Disease Program

Breaking News

Gastroenterology Launch is now LIVE! Key Historical Publications and Literature Highlights Available Now

Breaking News

Sarcoidosis Awareness Month

Breaking News

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial

Publications

Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Podcasts

IMID Author Interview: Dorthe Berthelsen, 2024

Podcasts

IMID Author Interview: Dr Jake Weddell, 2024

Podcasts

Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar

Podcasts

IMID Author Interview: Professor Frank Verhoeven, 2024

Podcasts

AxSpA Podcast: Long-term etanercept response and real-world effectiveness of tofacitinib and adalimumab

Podcasts

PsA Podcast: 2023 EULAR recommendations and improvements in PROs with deucravacitinib

Podcasts

Discussing RA: April 2024

Publications

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Publications

Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study

Publications

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial

Publications

Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial

Publications

Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis

Podcasts

Author Interview: Professor Maria Antonietta D’Agostino, 2024

Podcasts

Author Interview: Professor Dennis McGonagle, 2024

Publications

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

Publications

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: A post hoc analysis of a Phase 3b/4 randomised safety study

Podcasts

AxSpA Podcast: Secukinumab retention over time & sacroiliac joint improvements between DMARDs

Podcasts

Author Interview: Dr Jürgen Rech, 2024

Podcasts

PsA Podcast: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population

Podcasts

Discussing Rheumatology: March 2024

Publications

Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study

Publications

Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE

Publications

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials

Publications

Long-term etanercept response for patients with radiographic axial spondyloarthritis based on achievement of early, intermediate, or late responses during index studies

Podcasts

AxSpA Podcast: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment

Publications

Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients

Publications

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA